GBA to decide on future of Merck's ezetimibe after German assessment sees no benefit
This article was originally published in Scrip
IQWiG, Germany's Institute for Quality and Efficacy in Healthcare, says that the benefits of the hypolipidaemic combination product ezetimibe are not clear. The institute's report does not bode well for Merck & Co, which markets Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin). The company must not await the verdict of the GBA, the Federal Joint Committee, which makes decisions on reimbursement, whether or not to take action on the report. It "undermines the drug and adds weight to the argument that it should not be prescribed so widely," says Gideon Heap, an analyst at Datamonitor.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.